Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S.
Benatar M, et al.
Neurotherapeutics. 2022 Sep;19(5):1686. doi: 10.1007/s13311-022-01286-9.
Neurotherapeutics. 2022.
PMID: 36175782
Free PMC article.
No abstract available.